Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer

References

• Cancer facts and figures 2017(US). Atlanta (GA): American Cancer Society(US); 2017.
   Google Scholar
• A report, Over 17 lakh new cancer cases in India by 2020: ICMR; 2016. Available from: http://icmr.nic.in/icmrsql/archive/2016/7.pdf
   Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784.
   PubMed Web of Science ®Google Scholar
• Khan O, Thangue L. NB HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2011;90:85–94.
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202.
   PubMed Web of Science ®Google Scholar
• Jacobson S, Pillus L. Modifying chromatin and concepts of cancer. Curr Opin Genet Dev. 1999;9:175–184.
   PubMed Web of Science ®Google Scholar
• Tambunan USF, Parikesit AA. HPV bioinformatics: in silico detection, drug design and prevention agent development. In: Topics on cervical cancer with an advocacy for prevention. Croatia: Intech Publishing; 2012.
   Google Scholar
• Singh VK, Kumar N, Kalsan M, et al. Mechanism of induction: induced pluripotent stem cells (iPSCs). J Stem Cells. 2015;10:43.
   PubMedGoogle Scholar
• De Ruijter A, Van Gennip A, Caron H, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737–749.
   PubMed Web of Science ®Google Scholar
• Gregoretti I, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338:17–31.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38–51.
   PubMed Web of Science ®Google Scholar
• Hubbard T, Barker D, Birney E, et al. The Ensembl genome database project. Nucleic Acids Res. 2002;30:38–41.
   PubMed Web of Science ®Google Scholar
• Miller KM, Tjeertes JV, Coates J, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010;17:1144–1151.
   PubMed Web of Science ®Google Scholar
• Millard CJ, Watson PJ, Celardo I, et al. Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol Cell. 2013;51:57–67.
   PubMed Web of Science ®Google Scholar
• Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res. 2010;62:18–34.
   PubMed Web of Science ®Google Scholar
• Halkidou K, Gaughan L, Cook S, et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59:177–189.
   PubMed Web of Science ®Google Scholar
• Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001;92:1300–1304.
   PubMedGoogle Scholar
• Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat. 2005;94:11–16.
   PubMed Web of Science ®Google Scholar
• Wilson AJ, Byun D-S, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006; 281:13548–13558.
   PubMed Web of Science ®Google Scholar
• Song J, Noh JH, Lee JH, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005;113:264–268.
   PubMed Web of Science ®Google Scholar
• Huang B, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005;12:395–404.
   PubMed Web of Science ®Google Scholar
• Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5:455–463.
   PubMed Web of Science ®Google Scholar
• Baradari V, Huether A, Höpfner M, et al. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr-Relat Cancer. 2006;13:1237–1250.
   PubMed Web of Science ®Google Scholar
• Hahn CK, Ross KN, Warrington IM, et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci USA. 2008;105:9751–9756.
   PubMed Web of Science ®Google Scholar
• McKinsey TA. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol. 2012;52:303–319.
   PubMed Web of Science ®Google Scholar
• Thomas EA. Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol Neurobiol. 2009;40:33–45.
   PubMed Web of Science ®Google Scholar
• Rajak H, Kumar P, Parmar P, et al. Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors. Eur J Med Chem. 2012;53:390–397.
   PubMed Web of Science ®Google Scholar
• Geng L, Cuneo KC, Fu A, et al. Histone Deacetylase (HDAC) inhibitor LBH589 Increases Duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006;66:11298–11304.
   PubMed Web of Science ®Google Scholar
• Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev. 2005;25:261–309.
   PubMed Web of Science ®Google Scholar
• Kim YB, Ki SW, Yosnida M, et al. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot. 2000;53:1191–1200.
   PubMed Web of Science ®Google Scholar
• Nair SB, Teli MK, Pradeep H, et al. Computational identification of novel histone deacetylase inhibitors by docking based QSAR. Comput Biol Med. 2012;42:697–705.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247–1252.
   PubMed Web of Science ®Google Scholar
• Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5–17.
   PubMed Web of Science ®Google Scholar
• Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7:759–768.
   PubMed Web of Science ®Google Scholar
• Mohan R, Sharma AK, Gupta S, et al. Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line. Med. Chem Res. 2011;21:1156–1165.
   Web of Science ®Google Scholar
• Hamel E. Antimitotic natural products and their interactions with tubulin. Med Res Rev. 1996;16:207–231.
   PubMed Web of Science ®Google Scholar
• Batra JK, Jurd L, Hamel E. Structure/function studies with derivatives of 6-benzyl-1,3-benzodioxole, a new class of synthetic compounds which inhibit tubulin polymerization and mitosis. Mol Pharmacol. 1985;27:94–102.
   PubMed Web of Science ®Google Scholar
• Jurd L, Narayanan VL, Paull KD. In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against P388, L1210, B16, and M5076 murine models. J Med Chem. 1987; 30:1752–1756.
   PubMed Web of Science ®Google Scholar
• Yokota S, Kitahara M, Nagata K. Benzylidene lactam compound KNK347, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000;60:2942–2948.
   PubMed Web of Science ®Google Scholar
• Xia Y, Yang Z, Xia P, et al. Antitumor agents. Part 202: novel 2?-amino chalcones. Design, synthesis, and biological evaluation. Bioorg Med Chem Lett. 2000;10:699–701.
   PubMed Web of Science ®Google Scholar
• Chimirri A, Grasso S, Monforte AM, et al. Synthesis and antitumor activity evaluation of D2 -1,2,4-oxadiazolines. Pharmaco. 1996;51:125–129.
   Google Scholar
• Grasso S, Micale N, Monforte AM, et al. Synthesis and in vitro antitumour activity evaluation of 1-aryl-1H,3H-thiazolo[4,3-b]quinazolines. Eur J Med Chem. 2000;35:1115–1119.
   PubMed Web of Science ®Google Scholar
• Micale N, Zappala M, Grasso S. Synthesis and in vitro antitumor activity of 1-3-benzodioxole derivatives. Farmaco 2002;57:854–859.
   Google Scholar
• Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem. 2008;8:1555–1572.
   PubMed Web of Science ®Google Scholar
• Moroy G, Martiny VY, Vayer P, et al. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov Today. 2012;17:44–55.
   PubMed Web of Science ®Google Scholar
• Van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003;2:192–204.
   PubMed Web of Science ®Google Scholar
• Lovell SC, Davis IW, Arendall WB III, et al. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins. 2003;50:437–450.
   PubMed Web of Science ®Google Scholar
• Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2:1511–1519.
   PubMed Web of Science ®Google Scholar
• Lüthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature. 1992;5:83–85.
   Google Scholar
• Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35:407–410.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comp Chem. 2010;3:455–461.
   Google Scholar
• Ghoorah AW, Smail-Tabbone M, Devignes MD, Ritchie DW. Protein docking using case-based reasoning. Proteins. 2013;81:2150–2158.
   PubMed Web of Science ®Google Scholar
• Hartenfeller M, Zettl H, Walter M, et al. DOGS: reaction-driven de novo design of bioactive compounds. PLoS Comput Biol. 2012;8:e1002380.
   PubMed Web of Science ®Google Scholar
• Kubinyi H. Success stories of computer-aided design. In: Ekins S, editor. Computer applications in pharmaceutical research and development. Hoboken (NJ): John Wiley & Sons Inc; 2006.
   Google Scholar
• Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491–502.
   PubMed Web of Science ®Google Scholar
• Tsuji A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther Drug Monit. 1998;20:588–590.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:4.
   PubMed Web of Science ®Google Scholar